{"doi":"10.2967/jnumed.123.266388","title":"<sup>212</sup>Pb-Pretargeted Theranostics for Pancreatic Cancer","abstract":"Although pancreatic ductal adenocarcinoma (PDAC) is associated with limited treatment options and poor patient outcomes, targeted α-particle therapy (TAT) represents a promising development in the field. TAT shows potential in treating metastatic cancers, including those that have become resistant to conventional treatments. Among the most auspicious radionuclides stands the in&nbsp;vivo α-generator <sup>212</sup>Pb. Combined with the imaging-compatible radionuclide <sup>203</sup>Pb, this theranostic match is a promising modality rapidly translating into the clinic. <b>Methods:</b> Using the pretargeting approach between a radiolabeled 1,2,4,5-tetrazine (Tz) tracer and a <i>trans</i>-cyclooctene (TCO) modified antibody, imaging and therapy with radiolead were performed on a PDAC tumor xenograft mouse model. For therapy, 3 cohorts received a single administration of 1.1, 2.2, or 3.7 MBq of the pretargeting agent, [<sup>212</sup>Pb]Pb-DO3A-PEG<sub>7</sub>-Tz, whereby administered activity levels were guided by dosimetric analysis. <b>Results:</b> The treated mice were holistically evaluated; minimal-to-mild renal tubular necrosis was observed. At the same time, median survival doubled for the highest-dose cohort (10.7 wk) compared with the control cohort (5.1 wk). <b>Conclusion:</b> This foundational study demonstrated the feasibility and safety of pretargeted TAT with <sup>212</sup>Pb in PDAC while considering dose limitations and potential adverse effects.","journal":"Journal of Nuclear Medicine","year":2023,"id":321518,"datarank":0.5709993734655481,"base_score":3.8066624897703196,"endowment":3.8066624897703196,"self_citation_contribution":0.5709993734655481,"citation_network_contribution":0.0,"self_endowment_contribution":0.5709993734655481,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":44,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9579,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":268011,"name":"Lukas M. Carter","orcid":"0000-0003-4848-4190","position":1,"is_corresponding":false},{"id":1034143,"name":"Mohamed I. Atmane","orcid":null,"position":2,"is_corresponding":false},{"id":926859,"name":"Roberto De Gregorio","orcid":"0000-0001-6024-5913","position":3,"is_corresponding":false},{"id":615855,"name":"Alexa Michel","orcid":"0000-0002-7975-9612","position":4,"is_corresponding":false},{"id":893385,"name":"Spencer Kaminsky","orcid":null,"position":5,"is_corresponding":false},{"id":467193,"name":"Sébastien Monette","orcid":"0000-0003-2841-6887","position":6,"is_corresponding":false},{"id":326410,"name":"Mengshi Li","orcid":"0000-0003-3398-0183","position":7,"is_corresponding":false},{"id":326422,"name":"Michael K. Schultz","orcid":"0000-0002-4554-2212","position":8,"is_corresponding":false},{"id":235762,"name":"Jason S. Lewis","orcid":"0000-0001-7065-4534","position":9,"is_corresponding":false},{"id":640186,"name":"David Bauer","orcid":"0000-0002-3051-7997","position":0,"is_corresponding":true}],"reference_count":38,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T01:07:32.611759Z","pmid":"37945380","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}